United Kingdom · Biotechnology startup

F2G

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

Funding reportedLast round: Private equity

BiotechnologyManchester, United Kingdom

What company datasets say F2G raised

Funding, as reported

Reported in all283.3Min the source's currency
Rounds12
Last roundPrivate equity
Last round dateAug 2022
Investors listed20

Funding filed with regulators

F2G filed one raise, $17M in all. Filings say how much was sold and to how many investors; they never name the investors.

  1. Jul 2021$17MUK share allotment

Founders and team

From F2G's own website: 6 on the team.

  • Francesco Maria LavinoChief Executive Officer
  • Mark BaglinChief Commercial Officer
  • Ralf SchmidChief Financial Officer
  • Camilla SoenderbyNon-Executive Director
  • Lesley FittonExecutive Director, Clinical Operations
  • Tim AndersonNon-Executive Director

On 3 portfolio pages

Investors who name them

Each firm lists F2G on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Biotechnology in United Kingdom

Startups like it

Is this your company?

Add your raise, your deck and your story, and put F2G in front of investors. Or tell us what we have wrong.

List your startupSend a correction